For example, mutants in the fog-1 gene, which encodes a CPEB-related RNA-binding protein, also enhance the GSC defect of fbf-1 fbf-2 double mutants, but that enhancement is coupled to a reversal in germline sex and the mechanism remains a mystery (THOMPSON et al
Semaglutide is a GLP-1 receptor agonist that mimics the action of the hormone to regulate blood glucose, suppress appetite and slow gastric emptying
The final product, liraglutide (Victoza, Novo Nordisk), proved its effects in type 2 diabetes mellitus (T2DM) and was approved by the FDA in 2010 [19]
Side effects such as drowsiness, dizziness, nausea and vomiting, dry mouth, drug high, and others were reported in studies included in the systematic review, though none were severe
In July 2023, the company experienced a rapid increase in demand for the drug